title: In Response to: 'Impact of Glycosylation on Effector Functions of Therapeutic IgG' (Pharmaceuticals 2010, 3, 146-157).
abstract: To complete the review article by Abes and colleagues (Pharmaceuticals 2010, 3, 146-157) which provides a good overview on recently developed approaches for generation of glyco-modified antibodies and the impact of glyco-modification of antibodies on their effector functions, important information should be added, namely that - besides the Glycart and the Biowa approach to generate de-fucosylated antibodies - innovative, moss derived methods have been shown to generate glyco-modified antibodies with improved effector function profile.
authors.affiliation: Meridian Biopharmaceuticals GmbH, Brunnerstrasse 59, 1230 Wien, Austria. a.nechansky@meridian-biopharm.at.|Vela Pharmazeutische Entwicklung und Laboranalytik GmbH, Brunnerstrasse 59, 1230 Wien, Austria. a.nechansky@meridian-biopharm.at.
authors.forename: Andreas
authors.initials: A
authors.lastname: Nechansky
authors.affiliation: Vela Pharmazeutische Entwicklung und Laboranalytik GmbH, Brunnerstrasse 59, 1230 Wien, Austria. i.koller@vela-labs.at.
authors.forename: Iris
authors.initials: I
authors.lastname: Koller
authors.affiliation: Meridian Biopharmaceuticals GmbH, Brunnerstrasse 59, 1230 Wien, Austria. r.kircheis@virologik.com.|Virologik GmbH, Henkestrasse 91, 91052 Erlangen, Germany. r.kircheis@virologik.com.
authors.forename: Ralf
authors.initials: R
authors.lastname: Kircheis
keywords: ADCC; CDC; Fc -γRIII; glyco-modified IgG; therapeutic antibodies